According to investment banking sources, Glenmark Life Sciences (GLS), a unit of Glenmark Pharmaceuticals, will likely launch its Rs 1,600 crore initial public offering (IPO) later in July. Last week, the company filed an updated draft red herring prospectus (DRHP). The IPO includes a fresh issue of Rs 1,160 crore and the sale of 7.3 million shares by listed promoter Glenmark Pharmaceuticals.
Glenmark Life Sciences IPO is a main-board IPO of the face value of ₹2 aggregating up to ₹1,513.60 Crores. The issue is priced at ₹695 to ₹720 per equity share. The minimum order quantity is 20 Shares.
The IPO opens on Jul 27, 2021, and closes on Jul 29, 2021.
KFintech Private Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Glenmark Life Sciences is a pioneer in the development and production of Active Pharmaceutical Ingredients (APIs). By combining the potential of science, the company produces high-quality drugs. Over time, the company created strong relationships with leading global generic pharmaceutical companies, which aided in the expansion of product offerings and geographic reach.
The company collaborates with 16 of the world’s top 20 generic pharmaceutical companies & serves customers in multiple geographies including North America, Europe, Japan, Latin America, India, and ROW. Also places a strong emphasis on customer experience, and having a local presence in markets such as North America, the United Kingdom, and Latin America allows them to understand their customers’ needs.
The company produces and distributes high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, oncology, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It also provides contract development and manufacturing operations (CDMO) to specialty pharmaceutical companies.
- Leading producer of specialized APIs for chronic therapeutic areas such as CVS, CNS, diabetes, and pain management.
- Products can be exported to Europe, Latin America, North America, Japan, and the rest of the world.
- Strong relationships with the world’s leading generic companies.
- Proven track record of financial success.
- Manufacturing of high-quality products with R&D infrastructure.
Promoters and Financials
Glenmark Pharmaceuticals Limited is the promoter of the company.
kindly join our telegram channel my investment tracking